Menu
/REGISTER
Montecito
Pac Premier
Loading...
You are here:  Home  >  'pharmaceutical'  -  Page 2
Latest

Shire buying Conejo Valley’s Baxalta

By   /  Friday, January 15th, 2016  /  Central Coast Health Watch, Top Stories, Top Story  /  Comments Off on Shire buying Conejo Valley’s Baxalta

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen buys biotech company, partners with another

By   /  Wednesday, September 16th, 2015  /  Central Coast Health Watch, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen buys biotech company, partners with another

Thousand Oaks-based biopharmaceutical giant Amgen bought a Netherlands-based company and partnered with a Monrovia-based company in an effort to fend off competitors. Amgen announced Sept. 16 that it will buy Dezima, a biotech company focused on developing new treatments for dyslipidemia, a disease where a person has an abnormal amount of lipids in their blood. Read More →

Read More →
Latest

Amgen teams up with Merck on melanoma treatments

By   /  Thursday, February 6th, 2014  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen teams up with Merck on melanoma treatments

Thousand Oaks-based Amgen and pharmaceutical giant Merck are working together to evaluate the safety and effectiveness of combined treatments for melanoma patients.

Read More →
Latest

Amgen reports positive trial results for high-cholesterol treatment

By   /  Thursday, January 23rd, 2014  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen reports positive trial results for high-cholesterol treatment

The portion of Amgen’s Phase 3 trial of evolocumab that evaluated patients with high cholesterol who cannot tolerate statins has met goals related to percent reduction of low-density lipoprotein cholesterol.

Read More →
Latest

Amgen to buy KAI for $315M

By   /  Tuesday, April 10th, 2012  /  Latest news  /  Comments Off on Amgen to buy KAI for $315M

Amgen said April 10 that it plans to buy San Francisco-based KAI Pharmaceuticals for $315 million in cash in a deal that would give it worldwide rights to an experimental treatment for patients with chronic kidney disease. Thousand Oaks-based Amgen said the deal would give it worldwide rights, excluding in Japan, to KAI’s lead product, Read More →

Read More →